Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy

NCT00382811 is registered in ClinicalTrials.gov with MEI Pharma, Inc. as lead sponsor.

NCT NCT00382811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00382811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy
Lead sponsor
MEI Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2006
Completion date
April 30, 2011
Enrollment
142 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer, peritoneal neoplasms